Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $21.40.

A number of equities analysts have issued reports on the company. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. DA Davidson began coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th.

Cellebrite DI Trading Down 1.2%

NASDAQ CLBT traded down $0.19 during mid-day trading on Friday, reaching $15.94. 1,368,357 shares of the company’s stock traded hands, compared to its average volume of 1,968,646. Cellebrite DI has a 1-year low of $11.02 and a 1-year high of $19.98. The company has a fifty day simple moving average of $13.77 and a 200-day simple moving average of $14.53. The company has a market cap of $3.98 billion, a price-to-earnings ratio of 56.93, a P/E/G ratio of 1.97 and a beta of 1.17.

Insider Activity

In related news, CEO Thomas E. Hogan sold 103,188 shares of Cellebrite DI stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total value of $1,626,242.88. Following the completion of the transaction, the chief executive officer directly owned 590,777 shares in the company, valued at approximately $9,310,645.52. This trade represents a 14.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 158,191 shares of company stock worth $2,479,438. 5.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CLBT. Cooper Creek Partners Management LLC acquired a new position in Cellebrite DI in the third quarter worth $55,999,000. Granahan Investment Management LLC raised its holdings in shares of Cellebrite DI by 1,108.5% during the third quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock worth $48,721,000 after purchasing an additional 2,411,726 shares during the period. Capital International Investors bought a new position in shares of Cellebrite DI in the 4th quarter worth about $41,073,000. Invesco Ltd. lifted its position in shares of Cellebrite DI by 58.6% in the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after buying an additional 2,054,644 shares during the last quarter. Finally, Weiss Asset Management LP boosted its holdings in shares of Cellebrite DI by 3,485.3% in the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock valued at $26,180,000 after buying an additional 1,846,851 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.